BEST UNLIMITED TURBO LONG CERTIFICATE - BRISTOL-MYERS SQUIBB | Market Closed - Euronext Paris 12:30:01 2024-05-28 EDT | ||
| 0.995 EUR | -9.95% |
|
| Current month | -43.94% | ||
| 1 month | -47.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 0.995 | -9.95% |
| 24-05-27 | 1.105 | -1.78% |
| 24-05-24 | 1.125 | -7.41% |
| 24-05-23 | 1.215 | -9.67% |
| 24-05-22 | 1.345 | +0.75% |
Real-time Euronext Paris
Last update May 28, 2024 at 12:30 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| 4N89S | |
| ISIN | DE000SU9QAY0 |
| Date issued | 2024-02-21 |
| Strike | 35.6 $ |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 2.83 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.655 € |
|---|---|
| Lowest since issue | 0.995 € |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.49
USD
Average target price
53.19
USD
Spread / Average Target
+31.38%
- Stock Market
- Certificates
- 4N89S Certificat
